文献速递白血病

通过稳态负荷评估慢性髓性白血病患者的慢性应激负担

Estimating the burden of chronic stress through allostatic load in patients with chronic myeloid leukemia.
PubMed 文献 · Leukemia · 2025-09-11

该回顾性队列纳入194例慢性髓性白血病患者,用23项生物标志物计算稳态负荷(AL)。较高的AL与不良健康社会决定因素和行为因素相关,AL每升高1单位,达到最佳分子学缓解的比值降低18%(p=0.02)。全部11例进展至晚期CML和全部9例死亡均发生在高AL组。

要点

  • AL每升高1单位,达到最佳分子学缓解的比值降低18%(p=0.02)。
  • 全部11例疾病进展至晚期CML及全部9例死亡均发生于高AL组。
  • 较高的AL与极度贫困、交通受限、依赖公共医保及缺乏体力活动相关。

核心结论

  • AL可能作为整合生物标志物用于识别同时承受生理应激负担和社会劣势的高危CML患者。

研究设计与样本

  • 回顾性队列研究,纳入194例慢性髓性白血病患者,使用涵盖心血管、代谢、血液、肾脏和肝脏系统的23项生物标志物计算稳态负荷(AL)。

主要发现

  • 较高的AL与极度贫困(p=0.02)、交通获取受限(p=0.02)、依赖公共健康保险(p=0.03)和缺乏体力活动(p=0.05)相关。
  • AL每升高1单位,达到最佳分子学缓解的比值降低18%(p=0.02)。
  • 全部11例疾病进展至晚期CML和全部9例死亡均发生在高AL组,高AL组复合不良事件(包括分子学缓解丧失、TKI治疗失败、疾病进展和死亡)发生率更高(p=0.03)。

临床怎么用

  • 作者认为AL作为有前景的整合生物标志物,可帮助肿瘤科实践完善风险分层并实施个性化多学科干预。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite advances in tyrosine kinase inhibitor (TKI) therapy, outcomes in chronic myeloid leukemia remain (CML) highly variable, underscoring the need to explore determinants beyond conventional clinical indicators. This study examined the relationship between allostatic load (AL), a biomarker-based index of cumulative chronic stress, social determinants of health (SDH), and treatment outcomes. In a retrospective cohort of 194 patients, AL was calculated using 23 biomarkers spanning cardiovascular, metabolic, hematologic, renal, and hepatic systems. Higher AL was associated with adverse SDH and behavioral factors, including greater extreme poverty (p = 0.02), limited transportation access (p = 0.02), reliance on public health coverage (p = 0.03), and physical inactivity (p = 0.05). Each unit increase in AL reduced the odds of achieving optimal molecular response by 18% (p = 0.02). All 11 disease progressions to advanced CML and all 9 deaths occurred in the high AL group, who also had higher rates of composite adverse events, including loss of molecular response, TKI failure, disease progression, and mortality (p = 0.03). These findings position AL as a promising integrative biomarker to identify high-risk patients facing combined physiological stress burden and social disadvantage, enabling oncology practices to refine risk stratification and implement personalized, multidisciplinary interventions.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Miranda-Galvis M, Tjioe KC, Sharara M, et al. Estimating the burden of chronic stress through allostatic load in patients with chronic myeloid leukemia. Leukemia. 2025. PMID: 40935825. doi:10.1038/s41375-025-02763-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。